Ultrahuman posted $64 million in revenue and its first-ever profit in fiscal 2025, a 5.4x jump that helped it land a $70 million round led by Qualcomm Ventures — part of a smart ring category now growing faster than smartwatches.
Oura launched its first proprietary AI model on February 24, 2026, built specifically to give personalized cycle, fertility, pregnancy and menopause guidance using a member's own biometric data — all processed on Oura's own servers rather than sent to outside AI providers.
Nvidia unveiled a healthcare robotics platform, including a hospital digital-twin blueprint called Rheo, designed to train clinical robots in simulation before they ever touch a real patient.
A phishing attack on AI utilization-management vendor Xsolis exposed the medical and personal data of 1.4 million patients across eight U.S. health systems, including Mayo Clinic and UW Medicine.
Insilico Medicine has begun a Phase III trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, marking the first AI-discovered therapy for the disease to reach late-stage testing.
Illinois, Nevada, Rhode Island and Maine now ban AI chatbots from practicing therapy outright, while Utah, California and Colorado are instead forcing chatbots to disclose they're not human — a patchwork that's reshaping how AI mental-health apps operate state by state.
Johnson & Johnson's Ottava surgical robot finally won FDA authorization in July 2026 after more than a decade of delays, entering a soft-tissue robotic surgery market suddenly crowded with new AI-guided rivals.
Eli Lilly has switched on LillyPod, a 1,016-GPU NVIDIA supercomputer delivering over 9,000 petaflops — a bet that owning frontier-scale AI compute is now essential to compete in drug discovery.
Schrodinger has co-founded Tectora Therapeutics, a $55 million Series A-backed biotech built to develop two of its own AI-designed drug candidates for immunology and inflammation.
A Nature Cancer study spanning over 125,000 mammograms found Google's AI outperformed human radiologists on sensitivity while matching them on specificity — the largest NHS test yet of AI in breast cancer screening.